The blood-brain barrier protects the brain from poisons but also prevents drugs from reaching brain tumors; innovative new treatments are needed.
This laboratory study shows that a nanotechnology drug called SapC-DOPS crosses that barrier and targets brain-tumor cells and retards growth of tumor blood vessels. The findings also show how the agent targets tumor cells and recommend its further development as a novel treatment for glioblastoma.
An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier, kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
The laboratory and animal study also shows how the agent, called SapC-DOPS, targets tumor cells and blood vessels. The findings support further development of the drug as a novel treatment for brain tumors.
Glioblastoma multiforme is the most common and aggressive form of brain cancer, with a median survival of about 15 months. A major obstacle to improving treatment for the 3,470 cases of the disease expected in the United States this year is the blood-brain barrier, the name given to the tight fit of cells that make up the blood vessels in the brain. That barrier protects the brain from toxins in the blood but also keeps drugs in the bloodstream from reaching brain tumors.
“Few drugs have the capacity to cross the tumor blood-brain barrier and specifically target tumor cells,” says principal investigator Balveen Kaur, PhD, associate professor of neurological surgery and chief of the Dardinger Laboratory of Neurosciences at the OSUCCC – James. “Our preclinical study indicates that SapC-DOPS does both and inhibits the growth of new tumor blood vessels, suggesting that this agent could one day be an important treatment for glioblastoma and other solid tumors.”
The findings were published in a recent issue of the journal Molecular Therapy.
SapC-DOPS (saposin-C dioleoylphosphatidylserine), is a nanovesicle drug that has shown activity in glioblastoma, pancreatic cancer and other solid tumors in preclinical studies. The nanovesicles fuse with tumor cells, causing them to self-destruct by apoptosis.
Key findings of the study, which used two brain-tumor models, include:
The Latest Bing News on:
- Blocking Cholesterol Storage Could Stop Growth of Pancreatic Tumors, Says Studyon July 7, 2020 at 1:25 pm
Using a therapeutic compound, called SapC-DOPS, a nanovesicle to deliver a combined biomarker target therapy and standard chemotherapy for pancreatic cancer may show benefit to patients.
- New Potential Treatment for Pancreatic Canceron June 8, 2020 at 2:09 pm
‘Using a therapeutic compound, called SapC-DOPS, a nanovesicle (or a nanotechnology drug delivery system) made of microscopic components of a cell, to deliver a combined biomarker target therapy ...
- UC research points to potential new treatment for pancreatic canceron June 8, 2020 at 12:52 pm
Researchers in this study have found that using a therapeutic compound, called SapC-DOPS, a nanovesicle (or a nanotechnology drug delivery system) made of microscopic components of a cell, to deliver ...
- Combo therapy, nanoparticle delivery system show promise for pancreatic canceron June 8, 2020 at 8:03 am
The drug compound, called SapC-DOPS, combines chemotherapy with targeted therapy and is capable of killing the cells that cause a number of cancers, including pancreatic cancer, which is ...
- Potential therapy for rare neurologic disease discoveredon April 2, 2020 at 3:20 pm
The study, being published online April 6 in the journal EBioMedicine, revealed that the effects of a therapy delivery system using microscopic components of a cell (nanovesicles) called SapC-DOPS may ...
The Latest Google Headlines on:
The Latest Bing News on:
- Neurotransmitter-derived lipidoids help carry drugs across the blood-brain barrier in miceon July 24, 2020 at 3:03 pm
Biomedical engineers at the Tufts University School of Engineering have developed tiny lipid-based nanoparticles that incorporate neurotranmitters to help carry drugs, large molecules, and even gene ...
- Novel drug delivery particles use neurotransmitters as a 'passport' into the brainon July 24, 2020 at 11:04 am
Biomedical engineers at the Tufts University School of Engineering have developed tiny lipid-based nanoparticles that incorporate neurotranmitters to help carry drugs, large molecules, and even ...
- Healthcare Nanotechnology (Nanomedicine) Market Drivers, Challenges, and Competitive Landscape till 2022on July 23, 2020 at 1:21 am
The diagnosis field has more precise and reliable nanotechnology methods. These require minimum biological sample which facilitates considerable reduction in consumption of reagents and disposables.
- Vesigen Nabs $28M to Wrap “ARMMS” Around Large Molecule Drug Deliveryon July 22, 2020 at 1:03 pm
It’s not enough for a cell or gene therapy to reach a cell, it must also get inside it to access most of the validated drug targets. Vesigen Therapeutics ...
- MIT nanoparticles tag proteins to reveal disease via the breathon July 20, 2020 at 8:20 pm
Using the breath to gauge the health of our lungs and reveal diseases related to them is emerging as a diagnostic tool with huge potential, with a number of promising technologies on the horizon.
- Scientists pave way for new era of medicine by observing nanoparticles for 1st timeon July 20, 2020 at 7:30 am
Physicists have achieved a world first which could revolutionize the field of medicine by measuring and studying a single, twisted nanoparticle in isolation, paving the way for microscopic ‘labs’ to ...
- Single nanoparticles could pave the way for medicines on demandon July 20, 2020 at 12:59 am
For the first time, a single, twisted nanoparticle has been accurately measured and characterised in a lab, taking scientists one vital step closer to a time when medicines will be produced and ...
- New nano drug candidate kills aggressive breast cancer cellson July 19, 2020 at 11:29 pm
(Nanowerk News) Researchers at the University of Arkansas have developed a new nano drug candidate that kills triple negative breast cancer cells. Triple negative breast cancer is one of the most ...
- Light and nanoparticles against canceron July 16, 2020 at 7:29 am
Leiden Ph.D. student Xuequan Zhou has designed a new promising molecule that efficiently kills cancer cells, but does not harm healthy tissue. The trick: the drug is only active when irradiated with ...
- New promising treatment uses smart nanoparticles to target lung canceron July 15, 2020 at 5:41 pm
A new and promising approach for treatment of lung cancer has been developed. The treatment combines a novel surgical approach with smart nanoparticles to specifically target lung tumors.